多替阿巴拉米片在国内是否已上市？

Has it been launched in China? On January 22, 2018, the British multinational pharmaceutical company GlaxoSmithKline (GSK) announced that ViiV Healthcare, a joint venture of GSK, has officially launched the innovative AIDS treatment drug Dolutea (Suimeike) in the Chinese market. Dolutegra has been launched in China.

Dolutegra abalamib tablets are the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China. Dolutegra Abalami Tablets is a treatment plan based on DTG, an integrase inhibitor, as the core drug, coupled with two backbone drugs, abacavir and lamivudine, and is made into a single-tablet treatment for promotion, which has made great progress in the use of core drugs in HAART treatment. In addition, doptabalamid tablets can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving the patients' quality of life and work.

The recommended dosage of dolutegra tablets is one tablet, once daily. Adults or adolescents whose body weight is less than 40 kg should not be given dolutea as dolutea is a fixed-dose tablet and cannot be reduced. Because ingredients in Trimax may cause hypersensitivity reactions, patients should be screened for the HLA-B*5701 allele before starting treatment with abacavir-containing products, regardless of race. 

At present, dolutea palamid tablets have been approved for marketing in 50 countries and regions, and are recommended by many European and American academic institutions and guidelines as the first-line first-line treatment for patients with HIV infection. 

AIDS is generally recognized as a chronic disease. "For chronic diseases, patient compliance is particularly important. Taking one pill once a day reduces the frequency and dosage of medication and significantly enhances patient compliance." Xu Ding added, "In the past, disease control focused more on the front end, but now more and more attention is paid to the back end. How patients use medications and use them rationally also saves medical resources." The launch in my country has brought new treatment hope to domestic patients.